Skip to Content

Join the 'Chronic Obstructive Pulmonary Disease, Maintenance' group to help and get support from people like you.

Chronic Obstructive Pulmonary Disease, Maintenance News

Related terms: COPD, Maintenance

Fireworks Can Spark Bump in Air Pollution, Study Finds

Posted 1 Jul 2015 by Drugs.com

WEDNESDAY, July 1, 2015 – Most Americans know that fireworks can injure the eyes and hands, but these Fourth of July favorites can also take a toll on the lungs, a new study finds. Researchers from the National Oceanic and Atmospheric Administration (NOAA) found fireworks produce air pollutants, including tiny particles found in the air known as particulate matter. These microscopic particles of dust, dirt, soot, smoke and liquids can get inside the lungs and cause coughing, wheezing and shortness of breath. They can also lead to long-term health issues, such as asthma attacks, heart attack, stroke and even death in those with heart or lung disease. Using observations from 315 U.S. air quality-monitoring sites recorded from 1999 to 2013, the NOAA researchers quantified the surge in particulate matter that occurred on the nation's birthday. Specifically, they looked for particles that ... Read more

Related support groups: Asthma, Heart Disease, Chronic Obstructive Pulmonary Disease, Asthma - Maintenance, Chronic Obstructive Pulmonary Disease, Maintenance, Asthma - Acute, Chronic Obstructive Pulmonary Disease, Acute, Allergic Asthma, Ischemic Heart Disease, Reversible Airways Disease, Reversible Airways Disease - Maintenance

Health Tip: When Air Is Unhealthy

Posted 23 Jun 2015 by Drugs.com

-- Poor outdoor air quality may spur breathing problems among people with asthma or other respiratory issues. The American Lung Association advises: Be aware of the air quality and pollution levels each day in your area. Exercise indoors when air quality is poor, and restrict outdoor playtime for children. Cut down on driving by carpooling, biking or walking to work. Avoid burning wood or trash, and use battery-powered or electric lawn machinery instead of gas-powered devices. Keep indoor air quality healthier by prohibiting smoking at home. Read more

Related support groups: Asthma, Smoking, Chronic Obstructive Pulmonary Disease, Smoking Cessation, Asthma - Maintenance, Chronic Obstructive Pulmonary Disease, Maintenance, Asthma - Acute, Chronic Obstructive Pulmonary Disease, Acute, Allergic Asthma, Reversible Airways Disease, Reversible Airways Disease - Maintenance

Millions of Smokers May Have Undiagnosed Lung Disease

Posted 22 Jun 2015 by Drugs.com

MONDAY, June 22, 2015 – Millions of long-term smokers may have undiagnosed lung disease, a new study finds. Fifty-five percent of those who pass lung function tests still have a respiratory impairment, researchers report. But, using advanced imaging techniques along with walking and quality-of-life tests can reveal early signs of chronic obstructive pulmonary disease (COPD). An incurable, progressive disease, COPD is associated with smoking and is the third-leading cause of death in the United States, the researchers added. "Smokers who have 'normal' lung-function tests often have significant respiratory disease. Many of those smokers likely have the early stages of chronic obstructive pulmonary disease," study author Dr. Elizabeth Regan, an assistant professor of medicine at National Jewish Health in Denver, said in a hospital news release. "We hope these findings will help debunk the ... Read more

Related support groups: Smoking, Chronic Obstructive Pulmonary Disease, Smoking Cessation, Chronic Obstructive Pulmonary Disease, Maintenance, Lung Cancer, Chronic Obstructive Pulmonary Disease, Acute

COPD Patients Less Active, Which Can Worsen Outcomes

Posted 17 Jun 2015 by Drugs.com

WEDNESDAY, June 17, 2015 – People with chronic obstructive pulmonary disease (COPD) become less physically active, leading to further declines in their health, a new study shows. Decreased physical activity results in worsening lung function and overall health. Sustained inactivity is also associated with progression of muscle loss and inability to exercise, the researchers said. Their study of more than 130 people with COPD found that their physical activity decreased each year. The declines occurred regardless of the severity of their disease. Reduced physical activity was associated with an increase in breathing problems and decreases in overall health, quality of life and sense of well-being. Long-term physical inactivity was associated with larger declines in muscle mass and in 6-minute walk distance results. The study was published online recently in the American Journal of ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

FDA Approves Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for COPD

Posted 26 May 2015 by Drugs.com

RIDGEFIELD, Conn., May 26, 2015 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Stiolto Respimat is not indicated to treat asthma or acute deterioration of COPD. COPD, which includes chronic bronchitis and emphysema, is a serious but treatable lung disease. More than 15 million Americans have been told that they have COPD, but as many as 45 percent of the total estimated COPD cases in the U.S. remain undiagnosed. Patients are typically diagnosed when lung function is already significantly impaired. COPD symptoms can negatively impact a patient’s ability to br ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Spiriva, Chronic Obstructive Pulmonary Disease, Maintenance, Spiriva HandiHaler, Tiotropium, Olodaterol

COPD Raises Cardiac Death Risk for Those With Irregular Heartbeat

Posted 20 May 2015 by Drugs.com

WEDNESDAY, May 20, 2015 – Chronic obstructive pulmonary disease (COPD) increases the risk of all-cause and heart-related death in people with the common heart rhythm disorder known as atrial fibrillation, a new study finds. However, COPD doesn't increase the risk of stroke, the researchers said. COPD is a term used to describe the diseases emphysema and chronic bronchitis. COPD is the third leading cause of death in the United States, according to the U.S. Centers for Disease Control and Prevention. "Other studies have shown that COPD is an independent risk factor for cardiovascular disease, but what hadn't been studied was whether COPD was an independent risk factor for stroke, specifically among patients with atrial fibrillation," study author Dr. Michael Durheim, a pulmonary and critical care fellow at Duke University in Durham, N.C., said in an American Thoracic Society news ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Atrial Fibrillation, Arrhythmia, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

Rural Poor Bear Higher Burden of COPD, Study Finds

Posted 19 May 2015 by Drugs.com

TUESDAY, May 19, 2015 – Being poor and living in a rural area are two risk factors for chronic obstructive pulmonary disease (COPD), a new study finds. COPD is a progressive and incurable lung condition that involves a combination of emphysema and chronic bronchitis. It is often linked to smoking, and is the third leading cause of death in the world. In the new study, researchers led by author Dr. Sarath Raju of the Johns Hopkins School of Medicine in Baltimore reviewed data from almost 88,000 American adults older than 40. They found that 7.2 percent of them had COPD. However, the rate of COPD was closer to 12 percent among those who lived in poor and rural areas, Raju's team found. Why would people in rural areas be at higher risk? The reasons aren't clear, the team said. They said there's a need for research "to understand the potential contribution of occupational exposures, fuel ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Bronchitis, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

COPD Tied to Raised Risk for Sudden Cardiac Death

Posted 29 Apr 2015 by Drugs.com

WEDNESDAY, April 29, 2015 – Chronic obstructive pulmonary disease (COPD) is already the third leading cause of death in the world, and a new European study finds the respiratory illness might also raise a person's odds for sudden cardiac death. COPD is a progressive and incurable illness that involves a combination of emphysema and bronchitis, and is often tied to smoking. The researchers said that the disease has already been associated with an increased risk of heart disease and sudden cardiac death in certain high-risk patient populations. Now, the new study "shows that COPD is a risk indicator for sudden cardiac death in the general population, and that the risk increases with COPD severity," wrote a team led by Dr. Lies Lahousse, a postdoctoral researcher at Ghent University Hospital in Belgium. One expert in the United States said that even though the study can't prove that COPD ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute, Heart Block, Cardiac Arrhythmia

FDA Approves Spiriva Respimat (tiotropium) for the Maintenance Treatment of COPD

Posted 25 Sep 2014 by Drugs.com

Ridgefield, Conn., September 25, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat (tiotropium bromide) inhalation spray for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema and to reduce exacerbations in COPD patients. Boehringer Ingelheim anticipates Spiriva Respimat to be available in January 2015. Spiriva Respimat provides a pre-measured amount of medicine in a slow-moving mist that helps patients inhale the medicine. Spiriva Respimat was developed to actively deliver medication in a way that does not depend of how fast air is breathed in from the inhaler. Spiriva Respimat has the same active ingredient as Spiriva HandiHaler (tiotropium bromide inhalation powder), which is ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Spiriva, Chronic Obstructive Pulmonary Disease, Maintenance, Spiriva HandiHaler, Tiotropium

Combo Therapy Best for COPD: Study

Posted 16 Sep 2014 by Drugs.com

TUESDAY, Sept. 16, 2014 – A combination drug therapy aimed at opening the airways and reducing inflammation appears to be the best treatment for older adults with chronic obstructive pulmonary disease (COPD), especially those with asthma, a new study finds. COPD patients who received a combination of long-acting beta agonists and inhaled corticosteroids were less likely to die or require hospitalization because of their breathing disorder, compared to people receiving only one of the two medications, Canadian researchers report. The study findings were published in the Sept. 17 issue of the Journal of the American Medical Association. The findings go against the official guidelines for treating COPD, but actually support what most chest physicians are doing in the clinic, said lead author Dr. Andrea Gershon, a scientist with the Sunnybrook Health Sciences Center and the Institute for ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Advair Diskus, Advair HFA, Chronic Obstructive Pulmonary Disease, Acute, Breo Ellipta, Fluticasone/Salmeterol, Fluticasone/vilanterol

FDA Approves Striverdi Respimat - New Treatment for People With COPD

Posted 1 Aug 2014 by Drugs.com

FRIDAY, Aug. 1, 2014 – Patients with the progressive, deadly respiratory ailment known as chronic obstructive pulmonary disease (COPD) have a new weapon to battle the disease, the U.S. Food and Drug Administration said Thursday. The agency approved a new treatment, an inhaled spray called Striverdi Respimat (olodaterol) for COPD, the third leading killer of Americans. COPD, which is often linked to smoking, involves multiple lung conditions such as chronic bronchitis and emphysema. Patients with COPD may experience a number of symptoms, such as wheezing, coughing and tightness in their chest. According to the FDA, Striverdi Respimat belongs to a class of medicines known as long-acting beta-adrenergic agonists (LABAs). The agency said the drug works by helping the airway muscles in the lungs stay relaxed, and it can be taken once daily over a prolonged period of time. "The availability ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

Once-Daily Striverdi Respimat Inhaler Approved for COPD

Posted 31 Jul 2014 by Drugs.com

THURSDAY, July 31, 2014 – Striverdi Respimat (olodaterol) inhalation spray has been approved by the U.S. Food and Drug Administration to treat chronic obstructive pulmonary disease (COPD), the agency said Thursday in a news release. COPD, which includes chronic bronchitis and chronic emphysema, is a progressive disease that makes breathing difficult by obstructing airflow through the lungs. Most commonly caused by smoking, it's the third-leading cause of death in the United States, the FDA said. The once-daily inhaler relaxes lung airways, improving breathing. It was evaluated in a clinical study of more than 3,100 people diagnosed with COPD. The drug's label will carry a boxed warning that it increases the risk of asthma-related death. The FDA said Striverdi Respimat hasn't been evaluated among people with asthma and is not approved to treat asthma or sudden breathing problems such as ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease

Posted 31 Jul 2014 by Drugs.com

July 31, 2014 – Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema that are experiencing airflow obstruction. Striverdi Respimat can be used once daily over a long period of time. COPD is a serious lung disease that makes breathing difficult and worsens over time. Symptoms can include wheezing, cough, chest tightness, and shortness of breath. Cigarette smoking is the leading cause of COPD. According to the National Heart, Lung, and Blood Institute, COPD is the third leading cause of death in the United States. “The availability of this new long-term maintenance medication provides an additional treatment options for the millions of Americans who suffer with COPD,” said Curtis Rosebraugh, M.D., M.P.H., director of the Off ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

Annual COPD Costs To Hit $49 Billion by 2020: CDC

Posted 30 Jul 2014 by Drugs.com

WEDNESDAY, July 30, 2014 – Medical costs for chronic obstructive pulmonary disease (COPD) in the United States are more than $32 billion each year, according to new research from the U.S. Centers for Disease Control and Prevention. The yearly financial toll of COPD (which includes emphysema and chronic bronchitis) is expected to reach an estimated $49 billion by 2020. "For the first time, our analyses provide state-specific costs for COPD, which provide state public health practitioners with estimates of the economic burden of COPD within their borders and illustrates the potential medical and absenteeism costs savings to states through implementing state level programs that are designed to prevent the onset of COPD," Dr. Earl Ford, of the CDC's division of population health, said in a news release from the journal CHEST. Medical costs associated with COPD were primarily paid for by ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD

Posted 6 May 2014 by Drugs.com

London UK - 30 April 2014, GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK’s first once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonist (LAMA), and is contained in the Ellipta® inhaler. The FDA-approved strength is 62.5 mcg. Following this approval by the FDA, it is anticipated that launch activities in the US will commence during the fourth quarter of 2014. The phase III pivotal programme for umeclidinium included seven clinical studies which involved over 2,500 COPD patients treated with umeclidinium or placebo. About CO ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Chronic Obstructive Pulmonary Disease

Related Drug Support Groups

albuterol, Symbicort, Spiriva, Ventolin, Advair Diskus, Advair HFA, Combivent, Xopenex, Daliresp, view more... ProAir HFA, ipratropium, Proventil, Atrovent, salmeterol, Ventolin HFA, tiotropium, DuoNeb, Maxair, Alupent, formoterol, Brovana, Proventil HFA, Maxair Autohaler, Foradil Aerolizer, Tudorza Pressair, Atrovent HFA, Perforomist, albuterol / ipratropium, Serevent Diskus, Combivent Respimat, Volmax, Arcapta, Xopenex HFA, pirbuterol, levalbuterol, Ipratropium Inhalation Solution, arformoterol, Ipratropium Inhalation Aerosol, budesonide / formoterol, Spiriva Respimat, ProAir RespiClick, AccuNeb, roflumilast, indacaterol, aclidinium, Airet, Vospire ER, metaproterenol, fluticasone / salmeterol, Metaprel, Respirol, Xopenex Concentrate